Clinical research of the prediction of clinical outcome in patients with metastatic colorectal cancer treated with cetuximab
Not Applicable
Completed
- Conditions
- colorectal cancer
- Registration Number
- JPRN-UMIN000004993
- Lead Sponsor
- Cancer Chemotherapy Group in Ibaraki Cancer Clinical Epidemiology Study
- Brief Summary
The 9th Annual Meeting of Japanese Society of Medical Oncology KRAS and BRAF mutations as predictive/prognostic factors in patients with metastatic colorectal cancer treated with cetuximab
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
Not provided
Exclusion Criteria
1) Unable to assess the efficacy of cetuximab treatment 2) Other conditions not suitable for this study
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Progression-free survival and Overall survival
- Secondary Outcome Measures
Name Time Method Response rate, Grade 3 and more adverse events rate of interest to cetuximab